13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Mouse studies suggest inhibiting AKR1A1 or PKM2 could help treat acute kidney injury (AKI). In a mouse model of AKI, systemic AKR1A1 knockout or renal-specific PKM2 knockout increased survival and decreased tubular...
17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
14:11 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies suggest inhibiting PKM2 could help treat sepsis. In lipopolysaccharide (LPS)-pretreated mouse bone marrow-derived macrophages and a human monocytic cell line, PKM2 knockdown or a PKM2 inhibitor tool compound...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Pyruvate kinase M2 isozyme (PKM2)-targeting PET imaging agent for tumor detection

Imaging TECHNOLOGY: PET A PKM2-targeting PET imaging agent could help detect tumors. The agent consisted of an N,N-diarylsulfonamide that binds PKM2 - an enzyme expressed in all cancers and required for tumor glycolysis - linked...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Agios, Celgene deal

Celgene exercised its option under a 2010 cancer metabolism deal with Agios to license exclusive, worldwide rights to develop and commercialize Agios' AG-221 , an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) . The compound...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Agios, Celgene deal

Agios exercised its option under a 2010 cancer metabolism deal with Celgene to retain U.S. development and commercialization rights to the isocitrate dehydrogenase 1 (IDH1) program, including AG-120 . AG-120, an inhibitor of mutated IDH1,...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Agios, Celgene deal

Agios and Celgene extended by a year to April 2015 a 2010 cancer metabolism deal, triggering a $20 million payment to Agios. Celgene will now have five years of exclusivity, up from four years, during...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Pyruvate kinase M2 isozyme (PKM2); PKM1 Cell culture and mouse studies suggest targeting PKM2 may not be sufficient to inhibit...
08:00 , Jan 17, 2013 |  BC Innovations  |  Targets & Mechanisms

What to do with PKM2

Novartis AG researchers have shown that the absence of pyruvate kinase M2 isozyme has no effect on cancer cell proliferation in mice and suggest that inhibiting the enzyme alone might not be an effective strategy...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

ExperGen, Thallion cancer news

Thallion said it received a final binding award from the International Chamber of Commerce International Court of Arbitration rejecting all claims for damages by ExperGen in a dispute over a 2006 deal under which Thallion...